Advancing Trigeminal Neuralgia Research
At the core of the Trigeminal Neuralgia Association UK (TNA UK) is our unwavering commitment to research and the development. The focus on new treatments for Trigeminal Neuralgia (TN) stands as a beacon of hope. It’s with this dedication that we embrace groundbreaking initiatives like the Libra Study, a symbol of our resolve to deepen our understanding of TN. These initiatives offer real hope to those affected by this debilitating condition.
The Libra Study represents a significant leap forward in TN research. Endorsed by the Medicines and Healthcare Products Regulatory Agency (MHRA) and an ethics committee, this Phase II/III multicentre clinical trial will evaluate the efficacy and safety of Basimglurant. Targeting the mGlu5 receptors, Basimglurant promises a new path for reducing the neural overactivity and pain associated with TN. This is especially relevant for those who have found little solace in existing treatments.
Detailing the study at a training event
In recognition of the critical role of informed support, TNA UK recently hosted a comprehensive training session. Held in London, we welcomed our helpline volunteers and regional support leaders. This session, significantly enhanced by the participation of Dr Giorgio Lambru and his team, provided a deep dive into the details of the Libra Study. Dr Lambru, a leading figure in the field and Joint Chair of our Medical Advisory Board
offered invaluable insights into the trial, equipping our team with the knowledge needed to assist our members effectively. This training underscores our belief in the power of informed advocacy and support. It prepares us to navigate the complexities of TN treatment options with our community.
The Libra Study’s design is a testament to the meticulous approach taken towards evaluating Basimglurant’s potential. It encompasses an initial 8-week run-in phase for dosage adjustment. Following this, a 12-week double-blind phase. It then culminates in a 52-week open-label extension phase. This comprehensive structure will rigorously assess the treatment’s benefits and safety.
Criteria for participation
Our criteria for study participation is carefully considered. We welcome adults aged 18 to 75 diagnosed with primary or idiopathic TN. This approach is a reflection of our commitment to reaching those in urgent need of new treatment avenues. The study’s international footprint, spanning across continents, showcases its potential global impact as well as exemplifying TNA UK’s commitment to fostering international research collaboration.
Participant support is a cornerstone of the Libra Study, with all related travel and medical expenses covered to ensure accessibility. This aligns with TNA UK’s ethos, where the well-being and support of our members are paramount.
The enthusiasm and gratitude from our community has been profound, with members appreciating the opportunity to partake in critical research. One member eloquently shared their feelings: “A big thank you to our lovely TN association for telling me about the trial. I feel like I am able to do something for all my fellow sufferers. I am going into the trial full of optimism and hope.” These words beautifully capture the essence of our mission and the vital role of research in offering hope and enhancing the lives of those with TN.
As we forge ahead in supporting pivotal research projects like the Libra Study, the support of our members and the wider community remains invaluable. Through our collective efforts, we are poised to make significant advancements in the treatment of TN, improving the quality of life for those affected by this condition.
Together, we are not merely observers of the evolution of TN treatment. We contribute actively to a future where the challenges of Trigeminal Neuralgia are overcome. Hope is a tangible reality for every person facing this condition.
